U.S. Markets closed
  • S&P 500

    3,236.92
    -78.65 (-2.37%)
     
  • Nasdaq

    10,632.99
    -330.65 (-3.02%)
     
  • Russell 2000

    1,451.46
    -45.50 (-3.04%)
     
  • Crude Oil

    39.31
    -0.62 (-1.55%)
     
  • Gold

    1,860.00
    -8.40 (-0.45%)
     
  • Silver

    22.24
    -0.87 (-3.77%)
     
  • EUR/USD

    1.1663
    +0.0001 (+0.0117%)
     
  • 10-Yr Bond

    0.6760
    +0.0120 (+1.81%)
     
  • Vix

    28.58
    +1.72 (+6.40%)
     
  • GBP/USD

    1.2718
    -0.0007 (-0.0585%)
     
  • BTC-USD

    10,229.42
    -312.33 (-2.96%)
     
  • CMC Crypto 200

    207.71
    -6.26 (-2.92%)
     
  • FTSE 100

    5,899.26
    +69.80 (+1.20%)
     
  • Nikkei 225

    23,346.49
    -13.81 (-0.06%)
     

5 Value Stocks In The Healthcare Sector

Benzinga Insights

What Defines a Value Stock?

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.

The following stocks are considered to be notable value stocks in the healthcare sector:

  1. Genesis Healthcare (NYSE: GEN) - P/E: 1.79

  2. Vanda Pharmaceuticals (NASDAQ: VNDA) - P/E: 4.73

  3. XBiotech (NASDAQ: XBIT) - P/E: 1.0

  4. Salarius Pharmaceuticals (NASDAQ: SLRX) - P/E: 1.74

  5. Jaguar Health (NASDAQ: JAGX) - P/E: 0.09

Genesis Healthcare’s earnings per share for Q1 sits at 0.28, whereas in Q4, they were at -0.1. Genesis Healthcare does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

This quarter, Vanda Pharmaceuticals experienced a decrease in earnings per share, which was 0.08 in Q4 and is now 0.01. Vanda Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

XBiotech has reported Q4 earnings per share at -0.63, which has decreased by 320.0% compared to Q3, which was -0.15. XBiotech does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Salarius Pharmaceuticals has reported Q1 earnings per share at -0.22, which has increased by 50.0% compared to Q4, which was -0.44. Salarius Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Jaguar Health saw an increase in earnings per share from -1.62 in Q4 to -0.56 now. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.